Therapeutic-Dose LMWH Cuts Thromboembolism, Deaths in COVID-19
Reduction in venous thromboembolism, arterial thromboembolism, and deaths seen in high-risk patients in non-ICU, but not ICU, settings
Reduction in venous thromboembolism, arterial thromboembolism, and deaths seen in high-risk patients in non-ICU, but not ICU, settings
Long-term risks and consequences are considerable for patients receiving VKA, DOAC after first unprovoked VTE
Vaccination not associated with elevated risk for most of the adverse events examined; association found with increased risk for myocarditis, but risk higher in association with SARS-CoV-2 infection
For patients hospitalized with COVID-19 who are not critically ill, therapeutic-dose anticoagulation is beneficial
Risk for thrombosis doubled if catheter-to-vein ratio exceeds 45 percent for peripherally inserted central catheter
Bilateral deep vein thrombosis, single-session treatment, and female sex tied to greater risk
For discharged patients without suspected or confirmed VTE or other indication for anticoagulation, panel suggests not using anticoagulants
History of VTE predicts VTE occurrence; VTE occurrence linked to increased mortality
Researchers sought to assess the incidence of thrombotic complications in the second wave of patients with COVID-19, how many patients had diagnostic imaging for these complications, overall mortality, and then compared these outcomes with the first wave.
In a study, patients with moderate to severe CKD vs mild or no CKD had increased risk for death and recurrent venous thromboembolism.